Combining Multiple Comparisons and Modeling Techniques in Dose‐Response Studies
Abstract
Summary The analysis of data from dose‐response studies has long been divided according to two major strategies: multiple comparison procedures and model‐based approaches. Model‐based approaches assume a functional relationship between the response and the dose, taken as a quantitative factor, according to a prespecified parametric model. The fitted model is then used to estimate an adequate dose to achieve a desired response but the validity of its conclusions will highly depend on the correct choice of the a priori unknown dose‐response model. Multiple comparison procedures regard the dose as a qualitative factor and make very few, if any, assumptions about the underlying dose‐response model. The primary goal is often to identify the minimum effective dose that is statistically significant and produces a relevant biological effect. One approach is to evaluate the significance of contrasts between different dose levels, while preserving the family‐wise error rate. Such procedures are relatively robust but inference is confined to the selection of the target dose among the dose levels under investigation. We describe a unified strategy to the analysis of data from dose‐response studies which combines multiple comparison and modeling techniques. We assume the existence of several candidate parametric models and use multiple comparison techniques to choose the one most likely to represent the true underlying dose‐response curve, while preserving the family‐wise error rate. The selected model is then used to provide inference on adequate doses.
Citing Literature
Number of times cited according to CrossRef: 191
- Yves Dauvilliers, Gary Zammit, Ingo Fietze, David Mayleben, Dalma Seboek Kinter, Scott Pain, Jan Hedner, Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder, Annals of Neurology, 10.1002/ana.25680, 87, 3, (347-356), (2020).
- Gary Zammit, Yves Dauvilliers, Scott Pain, Dalma Sebök Kinter, Yosef Mansour, Dieter Kunz, Daridorexant, a new dual orexin receptor antagonist, in elderly subjects with insomnia disorder, Neurology, 10.1212/WNL.0000000000009475, 94, 21, (e2222-e2232), (2020).
- Xiaqing Huang, Byron J. Gajewski, Comparison of hierarchical EMAX and NDLM models in dose-response for early phase clinical trials, BMC Medical Research Methodology, 10.1186/s12874-020-01071-2, 20, 1, (2020).
- William J. Sandborn, Brian G. Feagan, Edward V. Loftus, Laurent Peyrin-Biroulet, Gert Van Assche, Geert D’Haens, Stefan Schreiber, Jean-Frederic Colombel, James D. Lewis, Subrata Ghosh, Alessandro Armuzzi, Ellen Scherl, Hans Herfarth, Lauren Vitale, Mohamed-Eslam F. Mohamed, Ahmed A. Othman, Qian Zhou, Bidan Huang, Roopal B. Thakkar, Aileen L. Pangan, Ana P. Lacerda, Julian Panes, Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn’s Disease, Gastroenterology, 10.1053/j.gastro.2020.01.047, (2020).
- Jingjing Chen, Tina Liu, Statistical considerations on implementing the MCP-Mod method for binary endpoints in clinical trials, Contemporary Clinical Trials Communications, 10.1016/j.conctc.2020.100641, (100641), (2020).
- Gustaf J. Wellhagen, Bengt Hamrén, Maria C. Kjellsson, Magnus Åstrand, Dose-Response Mixed Models for Repeated Measures – a New Method for Assessment of Dose-Response, Pharmaceutical Research, 10.1007/s11095-020-02882-0, 37, 8, (2020).
- Sofie Christiansen, Marta Axelstad, Martin Scholze, Hanna K.L. Johansson, Ulla Hass, Karen Mandrup, Henrik Lauritz Frandsen, Hanne Frederiksen, Louise Krag Isling, Julie Boberg, Grouping of endocrine disrupting chemicals for mixture risk assessment – Evidence from a rat study, Environment International, 10.1016/j.envint.2020.105870, 142, (105870), (2020).
- Ilya Lipkovich, Bohdana Ratitch, Cristina Ivanescu, Statistical Data Mining of Clinical Data, Quantitative Methods in Pharmaceutical Research and Development, 10.1007/978-3-030-48555-9, (225-315), (2020).
- Pierre Verweij, Parisa Danaietash, Bruno Flamion, Joël Ménard, Marc Bellet, Randomized Dose-Response Study of the New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension, Hypertension, 10.1161/HYPERTENSIONAHA.119.14504, (2020).
- Jihane Aouni, Jean Noel Bacro, Gwladys Toulemonde, Pierre Colin, Loic Darchy, Bernard Sebastien, Design optimization for dose-finding trials: a review, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2020.1730874, (1-12), (2020).
- Nigel Stallard, Lisa Hampson, Norbert Benda, Werner Brannath, Thomas Burnett, Tim Friede, Peter K. Kimani, Franz Koenig, Johannes Krisam, Pavel Mozgunov, Martin Posch, James Wason, Gernot Wassmer, John Whitehead, S. Faye Williamson, Sarah Zohar, Thomas Jaki, Efficient adaptive designs for clinical trials of interventions for COVID-19, Statistics in Biopharmaceutical Research, 10.1080/19466315.2020.1790415, (1-26), (2020).
- Yusuke Yamaguchi, Toshifumi Sugitani, Sample Size Allocation in Multiregional Dose-Finding Study Using MCP-Mod, Statistics in Biopharmaceutical Research, 10.1080/19466315.2020.1752298, (1-10), (2020).
- Marius Thomas, Björn Bornkamp, Martin Posch, Franz König, A multiple comparison procedure for dose‐finding trials with subpopulations, Biometrical Journal, 10.1002/bimj.201800111, 62, 1, (53-68), (2019).
- Shiyang Ma, Michael P. McDermott, Generalized multiple contrast tests in dose‐response studies, Statistics in Medicine, 10.1002/sim.8444, 39, 6, (757-772), (2019).
- Oleksandr Sverdlov, Yevgen Ryeznik, Weng Kee Wong, On Optimal Designs for Clinical Trials: An Updated Review, Journal of Statistical Theory and Practice, 10.1007/s42519-019-0073-4, 14, 1, (2019).
- Kathrin Möllenhoff, Frank Bretz, Holger Dette, Equivalence of regression curves sharing common parameters, Biometrics, 10.1111/biom.13149, 76, 2, (518-529), (2019).
- Marcus Maurer, Ana M. Giménez-Arnau, Gordon Sussman, Martin Metz, Diane R. Baker, Andrea Bauer, Jonathan A. Bernstein, Randolf Brehler, Chia-Yu Chu, Wen-Hung Chung, Inna Danilycheva, Clive Grattan, Jacques Hébert, Constance Katelaris, Michael Makris, Raisa Meshkova, Sinisa Savic, Rodney Sinclair, Karl Sitz, Petra Staubach, Bettina Wedi, Jürgen Löffler, Avantika Barve, Kenneth Kobayashi, Eva Hua, Thomas Severin, Reinhold Janocha, Ligelizumab for Chronic Spontaneous Urticaria, New England Journal of Medicine, 10.1056/NEJMoa1900408, 381, 14, (1321-1332), (2019).
- Jodi L. Karnell, Marius Albulescu, Stacey Drabic, Liangwei Wang, Rachel Moate, Manuel Baca, Vaheh Oganesyan, Michele Gunsior, Thomas Thisted, Li Yan, Jing Li, Ximing Xiong, Steven C. Eck, Melissa de los Reyes, Isharat Yusuf, Katie Streicher, Ulf Müller-Ladner, David Howe, Rachel Ettinger, Ronald Herbst, Jörn Drappa, A CD40L-targeting protein reduces autoantibodies and improves disease activity in patients with autoimmunity, Science Translational Medicine, 10.1126/scitranslmed.aar6584, 11, 489, (eaar6584), (2019).
- Byron J. Gajewski, Caitlyn Meinzer, Scott M. Berry, Gaylan L. Rockswold, William G. Barsan, Frederick K. Korley, Renee’ H. Martin, Bayesian hierarchical EMAX model for dose‐response in early phase efficacy clinical trials, Statistics in Medicine, 10.1002/sim.8167, 38, 17, (3123-3138), (2019).
- Lieven Nils Kennes, Gisela Volkers, Georg Kralidis, Study design aspects and inter‐subject variability in longitudinal clinical phase II dose‐finding trials, Pharmaceutical Statistics, 10.1002/pst.1921, 18, 2, (248-259), (2019).
- Qiqi Deng, Naitee Ting, Phase II Dose Finding, Statistical Methods in Biomarker and Early Clinical Development, 10.1007/978-3-030-31503-0, (301-320), (2019).
- Viktoria Hermann, Anastas Batalov, Svetlana Smakotina, Pierre-Eric Juif, Peter Cornelisse, First use of cenerimod, a selective S1P 1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study , Lupus Science & Medicine, 10.1136/lupus-2019-000354, 6, 1, (e000354), (2019).
- E. Albrecht, M. Reynvoet, N. Fournier, M. Desmet, Dose–response relationship of perineural dexamethasone for interscalene brachial plexus block: a randomised, controlled, triple‐blind trial, Anaesthesia, 10.1111/anae.14650, 74, 8, (1001-1008), (2019).
- Adriaan A. Voors, Jeroen J. Bax, Adrian F. Hernandez, Antonieta B. Wirtz, Akos F. Pap, Anna C. Ferreira, Michele Senni, Michael Laan, Javed Butler, Safety and efficacy of the partial adenosine A1 receptor agonist neladenoson bialanate in patients with chronic heart failure with reduced ejection fraction: a phase IIb, randomized, double‐blind, placebo‐controlled trial, European Journal of Heart Failure, 10.1002/ejhf.1591, 21, 11, (1426-1433), (2019).
- Lisa M. LaVange, Statistics at FDA: Reflections on the Past Six Years, Statistics in Biopharmaceutical Research, 10.1080/19466315.2019.1571322, 11, 1, (1-12), (2019).
- Olga V. Marchenko, Commentary on “Statistics at FDA: Reflections on the Past Six Years”, Statistics in Biopharmaceutical Research, 10.1080/19466315.2018.1554506, 11, 1, (17-19), (2019).
- Francesco De Pretis, Barbara Osimani, New Insights in Computational Methods for Pharmacovigilance: E-Synthesis, a Bayesian Framework for Causal Assessment, International Journal of Environmental Research and Public Health, 10.3390/ijerph16122221, 16, 12, (2221), (2019).
- Xiaowei Ren, Jielai Xia, An algorithm for computing profile likelihood based pointwise confidence intervals for nonlinear dose-response models, PLOS ONE, 10.1371/journal.pone.0210953, 14, 1, (e0210953), (2019).
- Francesco De Pretis, Jürgen Landes, Barbara Osimani, E-Synthesis: A Bayesian Framework for Causal Assessment in Pharmacosurveillance, Frontiers in Pharmacology, 10.3389/fphar.2019.01317, 10, (2019).
- Margaret Gamalo-Siebers, Lisa Hampson, Kattayoun Kordy, Sebastian Weber, Robert M. Nelson, Ronald Portman, Incorporating Innovative Techniques Toward Extrapolation and Efficient Pediatric Drug Development, Therapeutic Innovation & Regulatory Science, 10.1177/2168479019842541, (216847901984254), (2019).
- Saswati Saha, Werner Brannath, Comparison of different approaches for dose response analysis, Biometrical Journal, 10.1002/bimj.201700276, 61, 1, (83-100), (2018).
- A. Lawrence Gould, BMA‐Mod: A Bayesian model averaging strategy for determining dose‐response relationships in the presence of model uncertainty, Biometrical Journal, 10.1002/bimj.201700211, 61, 5, (1141-1159), (2018).
- Claire L. Smith, Yan Jin, Eyas Raddad, Terry A. McNearney, Xiao Ni, David Monteith, Roger Brown, Mark A. Deeg, Thomas Schnitzer, Applications of Bayesian statistical methodology to clinical trial design: A case study of a phase 2 trial with an interim futility assessment in patients with knee osteoarthritis, Pharmaceutical Statistics, 10.1002/pst.1906, 18, 1, (39-53), (2018).
- Qiqi Deng, Xiaofei Bai, Dacheng Liu, Dooti Roy, Zhiliang Ying, Dan‐Yu Lin, Power and sample size for dose‐finding studies with survival endpoints under model uncertainty, Biometrics, 10.1111/biom.12968, 75, 1, (308-314), (2018).
- Eric W. Gibson, Leadership in Statistics: Increasing Our Value and Visibility, The American Statistician, 10.1080/00031305.2017.1336484, 73, 2, (109-116), (2018).
- Simon Buatois, Sebastian Ueckert, Nicolas Frey, Sylvie Retout, France Mentré, Comparison of Model Averaging and Model Selection in Dose Finding Trials Analyzed by Nonlinear Mixed Effect Models, The AAPS Journal, 10.1208/s12248-018-0205-x, 20, 3, (2018).
- Eric Gibson, Frank Bretz, Michael Looby, Bjoern Bornkamp, Key Aspects of Modern, Quantitative Drug Development, Statistics in Biosciences, 10.1007/s12561-017-9203-2, 10, 2, (283-296), (2018).
- A. Toumazi, E. Comets, C. Alberti, T. Friede, F. Lentz, N. Stallard, S. Zohar, M. Ursino, dfpk: An R-package for Bayesian dose-finding designs using pharmacokinetics (PK) for phase I clinical trials, Computer Methods and Programs in Biomedicine, 10.1016/j.cmpb.2018.01.023, 157, (163-177), (2018).
- Bruce E Sands, William J Sandborn, Brian G Feagan, Gary R Lichtenstein, Hongyan Zhang, Richard Strauss, Philippe Szapary, Jewel Johanns, Julian Panes, Severine Vermeire, Christopher D O’Brien, Zijiang Yang, Kirk Bertelsen, Colleen Marano, Peficitinib, an Oral Janus Kinase Inhibitor, in Moderate-to-severe Ulcerative Colitis: Results From a Randomised, Phase 2 Study, Journal of Crohn's and Colitis, 10.1093/ecco-jcc/jjy085, 12, 10, (1158-1169), (2018).
- Tara J. Thrupp, Tamsin J. Runnalls, Martin Scholze, Subramaniam Kugathas, Andreas Kortenkamp, John P. Sumpter, The consequences of exposure to mixtures of chemicals: Something from ‘nothing’ and ‘a lot from a little’ when fish are exposed to steroid hormones, Science of The Total Environment, 10.1016/j.scitotenv.2017.11.081, 619-620, (1482-1492), (2018).
- Jun Yu, Xiangshun Kong, Mingyao Ai, Kwok Leung Tsui, Optimal designs for dose–response models with linear effects of covariates, Computational Statistics & Data Analysis, 10.1016/j.csda.2018.05.017, 127, (217-228), (2018).
- Alex Dmitrienko, Ralph B. D’Agostino, Multiplicity Considerations in Clinical Trials, New England Journal of Medicine, 10.1056/NEJMra1709701, 378, 22, (2115-2122), (2018).
- Xavier Paoletti, , , . . : . pages, ISBN: 9781498746106, Biometrical Journal, 10.1002/bimj.201800068, 60, 5, (1024-1025), (2018).
- Qing Liu, On Design and Analysis of Dose-Response Trials for Early Clinical Development, Biopharmaceutical Applied Statistics Symposium, 10.1007/978-981-10-7829-3_15, (377-403), (2018).
- Louise Ramhøj, Ulla Hass, Julie Boberg, Martin Scholze, Sofie Christiansen, Flemming Nielsen, Marta Axelstad, Perfluorohexane Sulfonate (PFHxS) and a Mixture of Endocrine Disrupters Reduce Thyroxine Levels and Cause Antiandrogenic Effects in Rats, Toxicological Sciences, 10.1093/toxsci/kfy055, 163, 2, (579-591), (2018).
- Qiqi Deng, Xiaofei Bai, Naitee Ting, Dynamic development paths for expanding a proof‐of‐concept study to explore dose range, Statistics in Medicine, 10.1002/sim.7840, 37, 22, (3244-3253), (2018).
- M. Worm, T. Higenbottam, O. Pfaar, R. Mösges, W. Aberer, K. Gunawardena, D. Wessiepe, D. Lee, M. F. Kramer, M. Skinner, B. Lees, S. Zielen, Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy, Allergy, 10.1111/all.13478, 73, 9, (1812-1822), (2018).
- James Dunyak, Patrick Mitchell, Bengt Hamrén, Gabriel Helmlinger, James Matcham, Donald Stanski, Nidal Al‐Huniti, Integrating dose estimation into a decision‐making framework for model‐based drug development, Pharmaceutical Statistics, 10.1002/pst.1841, 17, 2, (155-168), (2018).
- Lucy Kerns, Multiplicity-Adjusted Confidence Limits in Risk Assessment with Quantal Response Data, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2018.1452026, 28, 6, (1182-1192), (2018).
- Steven Novick, Shuyen Ho, Nicky Best, Data-Driven Prior Distributions for A Bayesian Phase-2 COPD Dose-Finding Clinical Trial, Statistics in Biopharmaceutical Research, 10.1080/19466315.2018.1462728, 10, 3, (166-175), (2018).
- Qiqi Deng, Kun Wang, Xiaofei Bai, Naitee Ting, A Cautionary Note When a Dose-Ranging Study is Used for Proving the Concept, Statistics in Biosciences, 10.1007/s12561-018-9224-5, (2018).
- Yevgen Ryeznik, Oleksandr Sverdlov, Andrew C. Hooker, Adaptive Optimal Designs for Dose-Finding Studies with Time-to-Event Outcomes, The AAPS Journal, 10.1208/s12248-017-0166-5, 20, 1, (2017).
- Frank Bretz, Kathrin Möllenhoff, Holger Dette, Wei Liu, Matthias Trampisch, Assessing the similarity of dose response and target doses in two non‐overlapping subgroups, Statistics in Medicine, 10.1002/sim.7546, 37, 5, (722-738), (2017).
- Yaohua Zhang, Qiqi Deng, Susan Wang, Naitee Ting, A Simple and Efficient Statistical Approach for Designing an Early Phase II Clinical Trial: Ordinal Linear Contrast Test, New Advances in Statistics and Data Science, 10.1007/978-3-319-69416-0_11, (179-196), (2017).
- Christy Chuang-Stein, Simon Kirby, Christy Chuang-Stein, Simon Kirby, Additional Topics, Quantitative Decisions in Drug Development, 10.1007/978-3-319-46076-5_13, (191-207), (2017).
- Christy Chuang-Stein, Simon Kirby, Christy Chuang-Stein, Simon Kirby, Choosing Metrics Appropriate for Different Stages of Drug Development, Quantitative Decisions in Drug Development, 10.1007/978-3-319-46076-5_6, (69-84), (2017).
- Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri, Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri, Bayesian Approach, Phase II Clinical Development of New Drugs, 10.1007/978-981-10-4194-5_11, (205-223), (2017).
- Paul Ratner, Charles P. Andrews, Frank C. Hampel, Bruce Martin, Dale E. Mohar, Denis Bourrelly, Parisa Danaietash, Sara Mangialaio, Jasper Dingemanse, Abdel Hmissi, Jay van Bavel, Efficacy and safety of setipiprant in seasonal allergic rhinitis: results from Phase 2 and Phase 3 randomized, double-blind, placebo- and active-referenced studies, Allergy, Asthma & Clinical Immunology, 10.1186/s13223-017-0183-z, 13, 1, (2017).
- Toshifumi Sugitani, Toshihiko Morikawa, Gatekeeping Strategies and Graphical Approaches in Clinical Trials with Hierarchically Structured Study Objectives: A Review, Japanese Journal of Biometrics, 10.5691/jjb.38.41, 38, 1, (41-78), (2017).
- Moreno Ursino, Sarah Zohar, Frederike Lentz, Corinne Alberti, Tim Friede, Nigel Stallard, Emmanuelle Comets, Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations, Biometrical Journal, 10.1002/bimj.201600084, 59, 4, (804-825), (2017).
- Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri, Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri, Data Analysis for Dose-Ranging Trials with Continuous Outcome, Phase II Clinical Development of New Drugs, 10.1007/978-981-10-4194-5_9, (155-182), (2017).
- Yijie Zhou, Su Chen, Danielle Sullivan, Yihan Li, Ying Zhang, Wangang Xie, Hongtao Zhang, Yuanyuan Tang, Li Wang, Alan Hartford, Bo Yang, Dose-ranging design and analysis methods to identify the minimum effective dose (MED), Contemporary Clinical Trials, 10.1016/j.cct.2017.08.005, 63, (59-66), (2017).
- Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri, Naitee Ting, Ding-Geng Chen, Shuyen Ho, Joseph C. Cappelleri, Data Analysis of Dose-Ranging Trials for Binary Outcomes, Phase II Clinical Development of New Drugs, 10.1007/978-981-10-4194-5_10, (183-204), (2017).
- Yasunori Aoki, Daniel Röshammar, Bengt Hamrén, Andrew C. Hooker, Model selection and averaging of nonlinear mixed-effect models for robust phase III dose selection, Journal of Pharmacokinetics and Pharmacodynamics, 10.1007/s10928-017-9550-0, 44, 6, (581-597), (2017).
- Christy Chuang-Stein, Simon Kirby, Christy Chuang-Stein, Simon Kirby, Designing Dose-Response Studies with Desired Characteristics, Quantitative Decisions in Drug Development, 10.1007/978-3-319-46076-5_8, (105-121), (2017).
- Cynthia Richards, Dan V Iosifescu, Rajnish Mago, Elias Sarkis, James Reynolds, Brooke Geibel, Matthew Dauphin, A randomized, double-blind, placebo-controlled, dose-ranging study of lisdexamfetamine dimesylate augmentation for major depressive disorder in adults with inadequate response to antidepressant therapy, Journal of Psychopharmacology, 10.1177/0269881117722998, 31, 9, (1190-1203), (2017).
- Neal Thomas, Understanding MCP‐MOD dose finding as a method based on linear regression, Statistics in Medicine, 10.1002/sim.7424, 36, 27, (4401-4413), (2017).
- Alex Dmitrienko, Ralph B. D'Agostino, Editorial: Multiplicity issues in clinical trials, Statistics in Medicine, 10.1002/sim.7506, 36, 28, (4423-4426), (2017).
- Jack Markham, Jun Liang, Aviva Levina, Rachel Mak, Bernt Johannessen, Peter Kappen, Chris J. Glover, Barry Lai, Stefan Vogt, Peter A. Lay, (Pentamethylcyclopentadienato)rhodium Complexes for Delivery of the Curcumin Anticancer Drug, European Journal of Inorganic Chemistry, 10.1002/ejic.201601331, 2017, 12, (1812-1823), (2017).
- Ulla Hass, Sofie Christiansen, Marta Axelstad, Martin Scholze, Julie Boberg, Combined exposure to low doses of pesticides causes decreased birth weights in rats, Reproductive Toxicology, 10.1016/j.reprotox.2017.05.004, 72, (97-105), (2017).
- Christian E. Elger, Seung Bong Hong, Christian Brandt, Linda Mancione, Jackie Han, Christine Strohmaier, BGG492 as an adjunctive treatment in patients with partial‐onset seizures: A 12‐week, randomized, double‐blind, placebo‐controlled, phase II dose‐titration study with an open‐label extension, Epilepsia, 10.1111/epi.13771, 58, 7, (1217-1226), (2017).
- Jan Rekowski, Claudia Köllmann, Björn Bornkamp, Katja Ickstadt, André Scherag, Phase II dose–response trials: A simulation study to compare analysis method performance under design considerations, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1293078, 27, 5, (885-901), (2017).
- Yuanyuan Tang, Chunyan Cai, Liangrui Sun, Jianghua He, Bayesian penalized log-likelihood ratio approach for dose response clinical trial studies, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1293081, 27, 6, (975-989), (2017).
- Martin Otava, Ziv Shkedy, Ludwig A. Hothorn, Willem Talloen, Daniel Gerhard, Adetayo Kasim, Identification of the minimum effective dose for normally distributed data using a Bayesian variable selection approach, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2017.1295247, 27, 6, (1073-1088), (2017).
- François Curtin, Stephane Heritier, The role of adaptive trial designs in drug development, Expert Review of Clinical Pharmacology, 10.1080/17512433.2017.1321985, 10, 7, (727-736), (2017).
- Jeff Maca, Suman Bhattacharya, Vladimir Dragalin, Paul Gallo, Michael Krams, Adaptive Seamless Phase II/III Designs—Background, Operational Aspects, and Examples, Drug Information Journal, 10.1177/216847900604000412, 40, 4, (463-473), (2017).
- Akram Ranjbar, Sara zebarjadi, Maryam Kazemi Naeini, Ali Reza Soltanian, A Mixed Effect Emax Model Applied for Determination of Malathion Optimal Dose, Avicenna Journal of Medical Biochemistry, 10.15171/ajmb.2017.08, 5, 1, (45-49), (2017).
- Joseph Wu, Anindita Banerjee, Bo Jin, Sandeep M Menon, Steven W Martin, Anne C Heatherington, Clinical dose–response for a broad set of biological products: A model-based meta-analysis, Statistical Methods in Medical Research, 10.1177/0962280216684528, (096228021668452), (2017).
- Suo-fu Ye, Jian Li, Shuang-min Ji, Hui-hui Zeng, Wei Lu, Dose-biomarker-response modeling of the anticancer effect of ethaselen in a human non-small cell lung cancer xenograft mouse model, Acta Pharmacologica Sinica, 10.1038/aps.2016.114, 38, 2, (223-232), (2016).
- Seung Jun Shin, Sujit K. Ghosh, A comparative study of the dose-response analysis with application to the target dose estimation, Journal of Statistical Theory and Practice, 10.1080/15598608.2016.1261260, 11, 1, (145-162), (2016).
- Jianan Peng, Wei Liu, Frank Bretz, Ziv Shkedy, Multiple confidence intervals for selected parameters adjusted for the false coverage rate in monotone dose–response microarray experiments, Biometrical Journal, 10.1002/bimj.201500254, 59, 4, (732-745), (2016).
- Georg Gutjahr, Björn Bornkamp, Likelihood ratio tests for a dose‐response effect using multiple nonlinear regression models, Biometrics, 10.1111/biom.12563, 73, 1, (197-205), (2016).
- Neal Thomas, Dooti Roy, Analysis of Clinical Dose–Response in Small-Molecule Drug Development: 2009–2014, Statistics in Biopharmaceutical Research, 10.1080/19466315.2016.1256229, 9, 2, (137-146), (2016).
- Juhee Lee, Peter F. Thall, Yuan Ji, Peter Müller, A decision-theoretic phase I–II design for ordinal outcomes in two cycles, Biostatistics, 10.1093/biostatistics/kxv045, 17, 2, (304-319), (2016).
- Alessio Crippa, Nicola Orsini, Dose-response meta-analysis of differences in means, BMC Medical Research Methodology, 10.1186/s12874-016-0189-0, 16, 1, (2016).
- Gernot Wassmer, Werner Brannath, Gernot Wassmer, Werner Brannath, Applications and Case Studies, Group Sequential and Confirmatory Adaptive Designs in Clinical Trials, 10.1007/978-3-319-32562-0_11, (241-276), (2016).
- Kirsten Schorning, Björn Bornkamp, Frank Bretz, Holger Dette, Model selection versus model averaging in dose finding studies, Statistics in Medicine, 10.1002/sim.6991, 35, 22, (4021-4040), (2016).
- B. Bieth, B. Bornkamp, C. Toutain, R. Garcia, J. P. Mochel, Multiple comparison procedure and modeling: a versatile tool for evaluating dose–response relationships in veterinary pharmacology – a case study with furosemide, Journal of Veterinary Pharmacology and Therapeutics, 10.1111/jvp.12313, 39, 6, (539-546), (2016).
- Kentaro Sakamaki, Toshifumi Kamiura, Yusuke Morita, Katsuhiro Iba, Seitaro Yoshida, Akira Wakana, Satoru Tsuchiya, Satoru Fukimbara, Hideki Suganami, Current Practice on Multiplicity Adjustment and Sample Size Calculation in Multi-arm Clinical Trials, Therapeutic Innovation & Regulatory Science, 10.1177/2168479016651660, 50, 6, (846-852), (2016).
- Jing Wang, Mark Chang, Sandeep Menon, Biomarker informed add-arm design for unimodal response, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2015.1052474, 26, 4, (694-711), (2015).
- David Ohlssen, Amy Racine, A Flexible Bayesian Approach for Modeling Monotonic Dose–Response Relationships in Drug Development Trials, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2014.919931, 25, 1, (137-156), (2015).
- Georg Ferber, Ekkehard Glimm, Translational Science Biostatistics, Principles of Translational Science in Medicine, 10.1016/B978-0-12-800687-0.00029-3, (267-280), (2015).
- Markus R. Lange, Heinz Schmidli, Analysis of clinical trials with biologics using dose–time‐response models, Statistics in Medicine, 10.1002/sim.6551, 34, 22, (3017-3028), (2015).
- C. Baayen, P. Hougaard, Confidence bounds for nonlinear dose–response relationships, Statistics in Medicine, 10.1002/sim.6566, 34, 27, (3546-3562), (2015).
- C. Baayen, P. Hougaard, C. B. Pipper, Testing effect of a drug using multiple nested models for the dose–response, Biometrics, 10.1111/biom.12276, 71, 2, (417-427), (2015).
- Holger Dette, Stefanie Titoff, Stanislav Volgushev, Frank Bretz, Dose response signal detection under model uncertainty, Biometrics, 10.1111/biom.12357, 71, 4, (996-1008), (2015).
- Francois Mercier, Bjoern Bornkamp, David Ohlssen, Erik Wallstroem, Characterization of dose‐response for count data using a generalized MCP‐Mod approach in an adaptive dose‐ranging trial, Pharmaceutical Statistics, 10.1002/pst.1693, 14, 4, (359-367), (2015).
- Tamsin J. Runnalls, Nicola Beresford, Subramaniam Kugathas, Luigi Margiotta-Casaluci, Martin Scholze, Alexander P. Scott, John P. Sumpter, From single chemicals to mixtures—Reproductive effects of levonorgestrel and ethinylestradiol on the fathead minnow, Aquatic Toxicology, 10.1016/j.aquatox.2015.10.009, 169, (152-167), (2015).
- Weizhen Wang, Jianan Peng, A Step-Up Test Procedure to Find the Minimum Effective Dose, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2014.920854, 25, 3, (525-538), (2014).
- Joseph Wu, Sandeep Menon, Mark Chang, An Adaptive Staggered Dose Design for a Normal Endpoint, Journal of Biopharmaceutical Statistics, 10.1080/10543406.2014.920862, 25, 4, (731-756), (2014).
- See more




